Sage Therapeutics, Inc. (SAGE) News
Filter SAGE News Items
SAGE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SAGE News Highlights
- SAGE's 30 day story count now stands at 4.
- Over the past 13 days, the trend for SAGE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- BIIB, DEC and DRUG are the most mentioned tickers in articles about SAGE.
Latest SAGE News From Around the Web
Below are the latest news stories about SAGE THERAPEUTICS INC that investors may wish to consider to help them evaluate SAGE as an investment opportunity.
11 Most Promising Psychedelic Stocks According to Hedge FundsIn this piece, we will take a look at the 11 most promising psychedelic stocks according to hedge funds. If you want to skip our overview of the psychedelic industry and the latest news, then you can take a look at the 5 Most Promising Psychedelic Stocks. The ability to use chemicals to alter one’s […] |
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.ZURZUVAE, the first and only oral, once-daily, 14-day treatment course, has shown to provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3 for women with PPD Patient support program, ZURZUVAE For You, and financial assistance available to eligible women with PPD prescribed ZURZUVAE Patients will receive prescriptions directly at home via specialty pharmacy distribution model CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therap |
Why Is Sage Therapeutics, Inc. (SAGE) Up 12.7% Since Last Earnings Report?Sage Therapeutics, Inc. (SAGE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Strong week for Sage Therapeutics (NASDAQ:SAGE) shareholders doesn't alleviate pain of five-year lossLong term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut... |
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q3 2023 Earnings Call TranscriptSage Therapeutics, Inc. (NASDAQ:SAGE) Q3 2023 Earnings Call Transcript November 7, 2023 Operator: Good morning. Welcome to Sage Therapeutics’ Third Quarter 2023 Conference Call. [Operator Instructions]. This call is being webcast live on the Investors and Media section of Sages’ website at sagerx.com. This call is the property of Sage Therapeutics and recording, reproduction or […] |
Sage Therapeutics (SAGE) Q3 Earnings Lag Estimates, Down 5%Sage Therapeutics (SAGE) reports dismal third-quarter results. It intends to price the recently approved oral postpartum depression pill Zurzuvae at $15,900 for an entire 14-day treatment course. |
Biogen’s Earnings Top Estimates. Wall Street Still Has Questions About Growth.Wall Street is interested in updates on future developments, rather than the latest quarter's numbers. |
Sage Therapeutics to Present at Upcoming November Investor ConferencesCAMBRIDGE, Mass., November 08, 2023--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the following upcoming investor conferences in November: |
Why Sage Therapeutics Stock Sank TodayIt wasn't a wise move for investors to hold or buy Sage Therapeutics (NASDAQ: SAGE) shares on Tuesday. For the quarter, Sage posted revenue that landed just shy of $2.72 million. Prognosticators had been projecting a per-share net loss of $2.68. |
UPDATE 1-Biogen-Sage Therapeutics postpartum depression pill priced at $15,900Sage Therapeutics has priced the oral postpartum depression (PPD) pill it developed with partner Biogen at $15,900 for a full 14-day course of treatment, the company said on Tuesday, months after the drug was approved by the U.S. health regulator. The companies had sought U.S. approval for Zurzuvae to treat clinical depression, a much larger market, and postpartum depression, but the Food and Drug Administration in August approved it only for PPD. Zurzuvae is the first oral pill for the condition that affects one in seven mothers after childbirth. |